

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen

312-265-9674

bsorensen@zacks.com

scr.zacks.com

101 N. Wacker Drive, Chicago, IL 60606

Nurexone Biologic

(OTCQB:NRXBF—TSXV:NRX)

NRXBF: Test Results Show Spinal Injury Recovery

NRXBF is a preclinical stage biotech company developing a treatment for spinal cord injuries. We value NRXBF at \$3.50/share using the discounted cash flow method and a 20% discount rate.

Current Price (07/08/25) \$0.49
Valuation \$3.50

OUTLOOK

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area.

The company announced results from preclinical testing that showed higher doses of ExoPTEN resulted in subjects regaining mobility after a spinal cord injury. This further illustrates the breakthrough potential of ExoPTEN.

SUMMARY DATA

52-Week High \$0.59
52-Week Low \$0.38
One-Year Return (%) N/A
Beta N/A
Average Daily Volume (sh) 8,172

Shares Outstanding (mil) 80
Market Capitalization (\$mil) \$39
Short Interest Ratio (days) 1
Institutional Ownership (%) N/A
Insider Ownership (%) N/A

Annual Cash Dividend \$0.00
Dividend Yield (%) 0.00

5-Yr. Historical Growth Rates

Sales (%) N/A
Earnings Per Share (%) N/A
Dividend (%) N/A

P/E using TTM EPS N/A

P/E using 2024 Estimate N/A

P/E using 2025 Estimate N/A

Risk Level

Type of Stock
Industry

High
Small-Cap
Biotech

ZACKS ESTIMATES

Revenue

(in millions of \$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	NA	NA	NA	NA	0 A
2024	0 A	0 A	0 A	0 A	0 A
2025	0 E	0 E	0 E	0 E	0 E
2026	0 E	0 E	0 E	0 E	0 E

Earnings per share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	NA	NA	NA	NA	-0.08 A
2024	-0.02 A	-0.04 A	-0.02 A	-0.01 A	-0.08* A
2025	-0.02 A	-0.02 E	-0.02 E	-0.02 E	-0.08 E
2026	-0.02 E	-0.02 E	-0.01 E	-0.01 E	-0.06 E

*Difference due to rounding

Update

NurExone is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point, the company, late last year, announced some preclinical test results that have the potential to benefit thousands of patients and increase the value of NRXBF to investors. More recently, however, the company announced preclinical results that are encouraging for the first condition mentioned above.

Company management announced that its preclinical study on ExoPTEN for the treatment of spinal cord injuries demonstrated that higher doses of the treatment led to regained motor function after a spinal cord injury. The study was conducted on small animals, which were given differing doses of ExoPTEN on the day of spinal compression surgery. The results show that 100% of animals treated with the higher dose regained walking ability in both front and hind legs, while only 1 out of 6 of the untreated animals achieved that milestone. This is an exciting result and provides further proof of the potential for ExoPTEN to be game-changing treatment.

To further the process, the company plans to initiate a Phase 1/2a clinical trial in the area of acute spinal cord injuries for ExoPTEN in 2026. Management detailed the study plans as involving adult patients with traumatic spinal cord injuries between spinal level C5 and T10. Those patients will be treated within 3-to-7-day post injury. This marks a significant step forward for the company in our view and, given the preclinical results that we have outlined, we expect the trial to yield exciting results.

As a reminder, spinal injuries aren't the only condition being targeted. Company management recently announced significant findings from an expanded study of ExoPTEN for repairing optic nerve damage. Using a rodent model of optic nerve crush to simulate damage associated with conditions such as glaucoma. Analysis of the data showed clear recovery of signal transmission in treated eyes compared to untreated controls, which showed no significant response.

According to the company, the study also showed significantly enhanced the survival of retinal ganglion cells, which are key neurons responsible for transmitting visual information to the brain.

We were also encouraged to hear comments from the lead investigator at the Goldschleger Eye Institute, part of a top hospital the company is collaborating with, when Dr. Ifat Sher said, "the results from this expanded study are extremely encouraging. ExoPTEN demonstrates potential as a treatment that restores functionality and offers neuroprotection. The study shows clear signal recovery, healthier optic nerve structures and preserved retinal ganglion cells. These results suggest that ExoPTEN could fundamentally change how we approach conditions like glaucoma and optic nerve trauma."

With a market size of approximately \$5.5 billion currently, based on estimates cited by the company, and a projected growth rate of over 8% annually, the potential for this treatment is extensive and is an exciting addition to the company's portfolio.

As a reminder, the company's ExoPTEN therapy has received the Orphan Medicinal Product Designation by the European Medicines Agency (EMA). According to the company, the EMA's Orphan Medicinal Product Designation offers incentives, including ten years of market exclusivity upon approval, access to grants and incentives from the European Commission and member states. Additionally, the company may benefit from free or reduced-cost scientific advice and assistance with clinical trial design, which can streamline the regulatory process and reduce development costs. Lastly, some European Union countries also provide tax credits and other financial incentives to support orphan drug development.

As we've noted before, the company received the Orphan Drug Designation for ExoPTEN in 2023 from the FDA in the United States. This designation was created by the FDA which noted that supporting the development and evaluation of new treatments for rare diseases is a key priority for the agency. The FDA has authority to grant orphan drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives including:

- Tax credits for qualified clinical trials
- Exemption from user fees
- Potential seven years of market exclusivity after approval


It was earlier test results from the use of ExoPTEN that sparked our enthusiasm for the company, because the initial test results are, in our view, truly remarkable. This isn't a potential treatment that was arrived at quickly or easily as research began at the University level and was conducted between January 2017 and May 2020, including testing the use of intranasal administration of exosomes driven from mesenchymal stem cells loaded with siRNA (a process that is described in more detail below). Testing targeted a complete spinal cord transection in rats, which is the strictest animal testing model, successfully demonstrating significant functional recovery. The company notes that the technology is successfully proven in additional preclinical studies, demonstrating that intranasal administration of ExoPTEN led to significant motor improvement, sensory recovery, and faster urinary reflex restoration. As mentioned, the research began at the University level and the Company has been granted an exclusive worldwide license from the Technion and Tel Aviv University, which includes a patent application, to develop and commercialize the technology. In addition, the Company has developed its own intellectual property and now has five families of patents.

We continue to be enthusiastic about the prospects for NurExone and suggest that US investors follow the Canadians and look into NRXBF. We urge investors with a higher risk tolerance to take a look at NRXBF and consider whether this compelling story may be of interest.

PROJECTED INCOME STATEMENT & BALANCE SHEET

Nurexone Biologic Income Statement and Balance Sheet										
(US \$ in thousands, except per share data)										
	1Q2024A	2Q2024A	3Q2024A	4Q2024A	1Q2025A	2Q2025E	3Q2025E	4Q2025E	2026E	
Revenues										
Operating Expenses										
General and administrative	695	1,507	782	157	1,082	1,093	1,104	1,115	3,128	
Research and development	225	733	503	407	618	624	630	637	1,628	
Loss from operations	920	2,240	1,285	564	1,700	1,717	1,734	1,752	4,756	
Other income and (expenses)										
Finance (income)/expense	2	28	2	2	(22)	0	0	0	0	
Other income, net	45	-21	-69	202	0	0	0	0	0	
Total other (income) and expenses, net	47	7	(67)	204	(22)	0	0	0	0	
Other comprehensive (gain)/loss	0	0	0	0	16	0	0	0	0	
Net loss	967	2,247	1,218	768	1,694	1,717	1,734	1,752	4,756	
Basic and diluted loss per share	\$ 0.02	\$ 0.04	\$ 0.02	\$ 0.01	\$ 0.02	\$ 0.02	\$ 0.02	\$ 0.02	\$ 0.06	
Basic and diluted wtd avg common shares	56,528,121	61,488,044	63,528,644	65,417,289	73,605,050	73,678,655	73,752,334	73,826,086	73,899,912	
Assets										
Current Assets:										
Cash	3,255	2,385	2,523	700	588	559	531	504	479	
Securities and other current assets	422	399	300	934	776	737	700	665	632	
Total Current Assets	3,677	2,784	2,823	1,634	1,364	1,296	1,231	1,169	1,111	
Property, Plant and Equipment, net	394	445	736	759	740	725	711	696	683	
Right-of-use assets	71	63	55	48	36	35	35	34	33	
Other assets	-	-	-	-	-	-	-	-	-	
Total Assets	4,142	3,292	3,614	2,441	2,140	2,056	1,976	1,900	1,827	
Liabilities and stockholder equity										
Current liabilities:										
Accounts Payable	102	371	263	232	366	373	381	388	396	
Other current liabilities	260	175	172	166	187	191	195	198	202	
Total Current Liabilities	362	546	435	398	553	564	575	587	599	
Long-term Liabilities:										
Royalty Payments	78	64	71	78	56	55	55	54	54	
Liability Assoc. With Gov't Grants	-	-	149	173	184	186	188	190	191	
Lease Liability	71	107	31	31	31	31	32	32	32	
Total long-term liabilities	149	171	251	282	271	273	274	276	278	
Total liabilities	511	717	686	680	824	837	850	863	876	
Stockholders Equity										
Equity reserves	2,113	1,197	2,699	1,395	1,681	1,698	1,715	1,732	1,749	
Additional Paid-in capital	16,497	17,682	17,783	19,466	20,413	20,821	21,238	21,662	22,096	
Accumulated Deficit	(14,979)	(16,304)	(17,554)	(19,100)	(20,778)	(21,401)	(22,043)	(22,704)	(22,894)	
Total stockholders equity	3,631	2,575	2,928	1,761	1,316	1,118	909	691	951	
Total liabilities and stockholder equity	4,142	3,292	3,614	2,441	2,140	2,056	1,976	1,900	1,827	

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article. Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.